Ervand G. Paronikyan

Ervand G. Paronikyan

Auto-generated profile, based on publicly available information

Ervand G. Paronikyan

Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of Armenia, Yerevan, Armenia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
EPE. G. Paronikyan
E. G. Paronikyan
ANA. S. Noravyan
A. S. Noravyan
SASh. F. Akopyan
Sh. F. Akopyan
IDI. A. Dzhagatspanyan
I. A. Dzhagatspanyan
INI. M. Nazaryan
I. M. Nazaryan
RPRuzanna G. Paronikyan
Ruzanna G. Paronikyan


24 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SDShushanik Dashyan
Shushanik Dashyan
Eugene BabaevEugene Babaev
Eugene Babaev
EPErvand G. Paronikyan
Ervand G. Paronikyan
AAArmen G. Ayvazyan
Armen G. Ayvazyan
RPRuzanna G. Paronikyan
Ruzanna G. Paronikyan
LHLernik S Hunanyan
Lernik S Hunanyan
Background: Heterocyclic compounds and their fused analogs, which contain pharmacophore fragments such as pyridine, thiophene and pyrimidine rings, are of great interest due to their broad spectrum of biological activity. Chemical compounds containing two or more pharmacophore groups due to additional interactions with active receptor centers usually enhance biological activity and can even lead to a new type of activity. The search for new effective neurotropic drugs in the series of derivatives of heterocycles containing pharmacophore groups in organic, bioorganic and medical chemistry is a serious problem. Methods: Modern methodology of drugs involves synthesis, physicochemical study, molecular modeling and selection of active compounds through virtual screening and experimental evaluation of the biological activity of new chimeric compounds with pharmacophore fragments. For the synthesis of new compounds, classical organic methods were used and developed. For the evaluation of neurotropic activity of new synthesized compounds, some biological methods were used according to indicators characterizing anticonvulsant, sedative and antianxiety activity as well as side effects. For docking analysis, various soft ware packages and methods were used. Results: As a result of multistep reactions, 11 new, tri- and tetracyclic heterocyclic systems were obtained. The studied compounds exhibit protection against pentylenetetrazole (PTZ) seizures as well as some psychotropic effects. The biological assays evidenced that nine of the eleven studied compounds showed a high anticonvulsant activity by antagonism with pentylenetetrazole. The toxicity of the compounds is low, and they do not induce muscle relaxation in the studied doses. According to the study of psychotropic activity, it was found that the selected compounds have an activating behavior and anxiolytic effects on the “open field” and “elevated plus maze” (EPM) models. The data obtained indicate the anxiolytic (antianxiety) activity of the derivatives of tricyclic thieno[2,3-b]pyridines and tetracyclic pyridothieno[3,2-d]pyrimidin-8-ones, especially pronounced in compounds 3b–f and 4e. The studied compounds increase the latent time of first immobilization on the “forced swimming” (FS) model and exhibit antidepressant effects; compounds 3e and 3f especially exhibit these effects, similarly to diazepam. Docking studies revealed that compounds 3c and 4b bound tightly in the active site of γ-aminobutyric acid type A (GABAA) receptors with a value of the scoring function that estimates free energy of binding (∆G) at −10.0 ± 5 kcal/mol. Compound 4e showed the best affinity ((∆G) at −11.0 ± 0.54 kcal/mol) and seems to be an inhibitor of serotonin (SERT) transporter. Compounds 3c–f and 4e practically bound with the groove of T4L of 5HT_1A and blocked it completely, while the best affinity observed was in compound 3f ((∆G) at −9.3 ± 0.46 kcal/mol). Conclusions: The selected compounds have an anticonvulsant, activating behavior and anxiolytic effects and at the same time exhibit antidepressant effects.

1 February 2018 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
Eugene BabaevEugene Babaev
Eugene Babaev
YKY. I. Koval
Y. I. Koval
VRV. B. Rybakov
V. B. Rybakov
EPE. G. Paronikyan
E. G. Paronikyan
GSG. M. Stepanyan
G. M. Stepanyan
ISI. A. Shadrin
I. A. Shadrin

14 January 2022 in Arkivoc
Verified
Journal Article
Open access
SDShushanik Dashyan
Shushanik Dashyan
RPRuzanna G. Paronikyan
Ruzanna G. Paronikyan
SMSuren S. Mamyan
Suren S. Mamyan
EPErvand G. Paronikyan
Ervand G. Paronikyan

1 June 2012 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
EPE. G. Paronikyan
E. G. Paronikyan
SASh. F. Akopyan
Sh. F. Akopyan
ANA. S. Noravyan
A. S. Noravyan
IDI. A. Dzhagatspanyan
I. A. Dzhagatspanyan
RPRuzanna G. Paronikyan
Ruzanna G. Paronikyan
AAA. G. Akopyan
A. G. Akopyan